NEW YORK (GenomeWeb News) – Pressure Biosciences and Target Discovery have struck a multi-faceted agreement covering the development, manufacture, and co-marketing of reagents, PBI said today.
Under the agreement, TDI has licensed PBI to make and sell a line of TDI reagents that were designed to be used with PBI's Pressure Cycling Technology for preparing tissues for scientific analysis.
PBI said that using its PCT technology with TDI's reagents stabilizes the structure and function of membrane proteins when they are released from tissue samples.
The companies believe that the combined offering will fill the existing need in life sciences research for an automated method for extracting and recovering intact, functional proteins associated with cell membranes in tissue samples. Membrane proteins are used in new diagnostics, vaccines, and therapeutics, and they are involved in cell signaling, response, and transportation.
"The companies plan to develop additional products incorporating the TDI reagents for other tissue processing and extraction applications," Nate Lawrence, VP of marketing at PBI, said in a statement. "We plan to collaborate with TDI in the marketing and promotion of the TDI reagents in industry publications, at scientific meetings, on each company's website, through common collaborator studies, and at key industry trade shows."